[go: up one dir, main page]

CN112689635A - 一种1,7-萘啶类衍生物及其制备方法和用途 - Google Patents

一种1,7-萘啶类衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN112689635A
CN112689635A CN201980058423.XA CN201980058423A CN112689635A CN 112689635 A CN112689635 A CN 112689635A CN 201980058423 A CN201980058423 A CN 201980058423A CN 112689635 A CN112689635 A CN 112689635A
Authority
CN
China
Prior art keywords
hydroxy
naphthyridine
link
reaction
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980058423.XA
Other languages
English (en)
Other versions
CN112689635B (zh
Inventor
张颜
魏苗苗
张雪娇
米国瑞
安会
魏冰
郭谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN112689635A publication Critical patent/CN112689635A/zh
Application granted granted Critical
Publication of CN112689635B publication Critical patent/CN112689635B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

提供一种式(I)所示的化合物或其互变异构体、光学异构体、氮氧化物、溶剂化物、药学上可接受的盐或前药，所述化合物的制备方法，包含其的药物组合物及所述化合物或药物组合物在制备治疗或减轻患者的HIF相关和/或EPO相关的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980058423.XA 2018-09-05 2019-08-29 一种1,7-萘啶类衍生物及其制备方法和用途 Active CN112689635B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811032376.5A CN110878096A (zh) 2018-09-05 2018-09-05 一种1,7-萘啶类衍生物及其制备方法和用途
CN2018110323765 2018-09-05
PCT/CN2019/103354 WO2020048380A1 (zh) 2018-09-05 2019-08-29 一种1,7-萘啶类衍生物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN112689635A true CN112689635A (zh) 2021-04-20
CN112689635B CN112689635B (zh) 2023-08-04

Family

ID=69722776

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811032376.5A Pending CN110878096A (zh) 2018-09-05 2018-09-05 一种1,7-萘啶类衍生物及其制备方法和用途
CN201980058423.XA Active CN112689635B (zh) 2018-09-05 2019-08-29 一种1,7-萘啶类衍生物及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811032376.5A Pending CN110878096A (zh) 2018-09-05 2018-09-05 一种1,7-萘啶类衍生物及其制备方法和用途

Country Status (5)

Country Link
US (1) US11981669B2 (zh)
EP (1) EP3835300B1 (zh)
JP (1) JP7359844B2 (zh)
CN (2) CN110878096A (zh)
WO (1) WO2020048380A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235718A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
WO2024222890A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2007090068A2 (en) * 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101460497A (zh) * 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
CN106146490A (zh) * 2015-03-27 2016-11-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN108341777A (zh) * 2017-01-23 2018-07-31 四川科伦博泰生物医药股份有限公司 异喹啉酮类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
CN106146491B (zh) 2015-03-27 2017-12-12 沈阳三生制药有限责任公司 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2007090068A2 (en) * 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101460497A (zh) * 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
CN106146490A (zh) * 2015-03-27 2016-11-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN108341777A (zh) * 2017-01-23 2018-07-31 四川科伦博泰生物医药股份有限公司 异喹啉酮类化合物及其应用

Also Published As

Publication number Publication date
CN110878096A (zh) 2020-03-13
EP3835300A4 (en) 2021-09-29
EP3835300A1 (en) 2021-06-16
EP3835300B1 (en) 2025-02-19
WO2020048380A1 (zh) 2020-03-12
CN112689635B (zh) 2023-08-04
US11981669B2 (en) 2024-05-14
JP7359844B2 (ja) 2023-10-11
US20210332043A1 (en) 2021-10-28
JP2021536484A (ja) 2021-12-27

Similar Documents

Publication Publication Date Title
CN106573906A (zh) 哌啶‑二酮衍生物
HK1215179A1 (zh) 促红细胞生成素表达增强剂
CN108948002A (zh) 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN112689635B (zh) 一种1,7-萘啶类衍生物及其制备方法和用途
EP3590941A1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
JP2011042639A (ja) ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
WO2021238007A1 (zh) 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
WO2007121662A1 (en) Diphenyl urea derivatives as kinase inhibitors, compositions and uses thereof
CN112513041B (zh) 三环化合物
JP2011026251A (ja) ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
EP3130588A1 (en) Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
HUE034721T2 (hu) Szubsztituált 2-alkil-1-oxo-N-fenil-3-heteroaril-1,2,3,4-tetrahidroizokinolin-4-karboxamidok maláriaellenes terápiákhoz
JP2011168515A (ja) エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
CN112778273A (zh) 环酮并吡啶酮类化合物及其制备方法和用途
TW202412778A (zh) 一種脯氨醯羥化酶抑制劑及其用途
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2024022186A1 (zh) 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
TW202220961A (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
TWI905781B (zh) 脯胺醯羥化酶抑制劑及其用途
CN111825689B (zh) 一种二氢吡唑啉酮类化合物的晶型及其制备方法
WO2006132438A1 (ja) １，３－ベンゾチアジノン誘導体およびその用途
CN111825690B (zh) 一种phd抑制剂的新晶型及其制备方法
TW202448441A (zh) 脯氨醯羥化酶抑制劑及其用途
CN120817949A (zh) 作为wrn抑制剂的化合物及其应用
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant